Clinical trial
A Phase I Study of Tolerance and Pharmacokinetics of HX008 (a Humanized Monoclonal Antibody Targeting PD-1) Plus LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Locally Advanced or Metastatic Melanoma Who Have Experienced Progressed Disease in Previous Anti-PD-1 or PD-L1 Therapy.
NCT04756934 is registered in ClinicalTrials.gov with Taizhou HoudeAoke Biomedical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Tolerance and Pharmacokinetics of HX008 (a Humanized Monoclonal Antibody Targeting PD-1) Plus LP002 (a Humanized Monoclonal Antibody Targeting PD-L1) in Patients With Locally Advanced or Metastatic Melanoma Who Have Experienced Progressed Disease in Previous Anti-PD-1 or PD-L1 Therapy.
- Lead sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- August 20, 2020
- Completion date
- August 20, 2022
- Enrollment
- 63 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.